ATE464901T1 - Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen - Google Patents

Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen

Info

Publication number
ATE464901T1
ATE464901T1 AT04801138T AT04801138T ATE464901T1 AT E464901 T1 ATE464901 T1 AT E464901T1 AT 04801138 T AT04801138 T AT 04801138T AT 04801138 T AT04801138 T AT 04801138T AT E464901 T1 ATE464901 T1 AT E464901T1
Authority
AT
Austria
Prior art keywords
antagonist
pipamperone
serotonin
treatment
psychotic disorders
Prior art date
Application number
AT04801138T
Other languages
English (en)
Inventor
Erik Buntinx
Original Assignee
Pharmaneuroboost N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP03447279A external-priority patent/EP1547650A1/de
Priority claimed from US10/725,965 external-priority patent/US7884096B2/en
Priority claimed from CA2451798A external-priority patent/CA2451798C/en
Priority claimed from US10/752,423 external-priority patent/US7855195B2/en
Priority claimed from US10/803,793 external-priority patent/US20050119249A1/en
Priority claimed from CA 2461248 external-priority patent/CA2461248C/en
Priority claimed from EP04447066A external-priority patent/EP1576985A1/de
Priority claimed from EP04025035A external-priority patent/EP1541197B8/de
Priority claimed from US10/984,683 external-priority patent/US20050203130A1/en
Priority claimed from CA 2487529 external-priority patent/CA2487529A1/en
Application filed by Pharmaneuroboost N V filed Critical Pharmaneuroboost N V
Priority claimed from PCT/BE2004/000172 external-priority patent/WO2005053796A1/en
Publication of ATE464901T1 publication Critical patent/ATE464901T1/de
Application granted granted Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04801138T 2003-12-02 2004-12-02 Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen ATE464901T1 (de)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
EP03447279A EP1547650A1 (de) 2003-12-02 2003-12-02 Verwendung von D4 und 5-HT2A Antagonisten, inverse Agonisten order partielle Agonisten
CA2451798A CA2451798C (en) 2003-12-02 2003-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US10/725,965 US7884096B2 (en) 2003-12-02 2003-12-02 Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP04447001 2004-01-05
US10/752,423 US7855195B2 (en) 2003-12-02 2004-01-06 Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US10/803,793 US20050119249A1 (en) 2003-12-02 2004-03-18 Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2461248 CA2461248C (en) 2003-12-02 2004-03-18 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
EP04447066A EP1576985A1 (de) 2004-03-18 2004-03-18 Verwendung von Antagonisten, Inversagonisten oder partielle Agonisten des D4- und 5-HT2A Rezeptors
EP04025035A EP1541197B8 (de) 2003-12-02 2004-10-21 Verwendung von Pipamperon und einem SNDRI, SNRI oder SSRI zur Behandlung von Stimmungs- oder Angststörungen
JP2004349085A JP4571485B2 (ja) 2003-12-02 2004-11-04 Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
US10/984,683 US20050203130A1 (en) 2003-12-02 2004-11-09 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CA 2487529 CA2487529A1 (en) 2003-12-02 2004-11-15 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
PCT/BE2004/000172 WO2005053796A1 (en) 2003-12-02 2004-12-02 Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists

Publications (1)

Publication Number Publication Date
ATE464901T1 true ATE464901T1 (de) 2010-05-15

Family

ID=42134278

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04801138T ATE464901T1 (de) 2003-12-02 2004-12-02 Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen

Country Status (8)

Country Link
AT (1) ATE464901T1 (de)
DE (1) DE602004026781D1 (de)
DK (1) DK1708790T3 (de)
ES (1) ES2343962T3 (de)
HR (1) HRP20100376T1 (de)
PT (1) PT1708790E (de)
RS (1) RS51331B (de)
SI (1) SI1708790T1 (de)

Also Published As

Publication number Publication date
PT1708790E (pt) 2010-07-09
DE602004026781D1 (de) 2010-06-02
DK1708790T3 (da) 2010-06-21
SI1708790T1 (sl) 2010-09-30
HRP20100376T1 (hr) 2010-08-31
ES2343962T3 (es) 2010-08-13
RS51331B (sr) 2011-02-28

Similar Documents

Publication Publication Date Title
PL1708790T3 (pl) Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
EP1722850A4 (de) Verfahren und vorrichtung zur behandlung von obstruktiver schlafapnoe und schnarchen
CY2015025I2 (el) Μεθοδοι για την αντιμετωπιση της νοσου παρκινσον
DE50312143D1 (de) Vorrichtung zur temporären schienung von zehen
EP1598855A4 (de) Belichtungsvorrichtung und verfahren und verfahren zur herstellung einer vorrichtung
DE60329015D1 (de) Verfahren zur hemmung der acrylamidbildungund seine verwendung
DE60321130D1 (de) Variation von parametern zur neurostimulation
ATE494279T1 (de) Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate
DE602005020209D1 (de) System zur Evaluierung von Herzstörungen
EP1916964A4 (de) Implantate und verfahren zur behebung, ersetzung und behandlung von gelenkkrankheiten
ATE346082T1 (de) Glucocorticoidrezeptorliganden zur behandlung von stoffwechselstörungen
IL187248A0 (en) Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
ATE374030T1 (de) Kombination eines mglur2 antagonists und eines ache inhibitors zur behandlung von akuten und/oder chronischen neurologischen krankheiten
NO20033417L (no) Anvendelse av CD23-antagonister for behandling av neoplastiske forstyrrelser
ATE303379T1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid- derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE367160T1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
DE602004002231D1 (de) Knochenkontaktierendes Implantat mit stossdämpfenden Eigenschaften und Verfahren zu dessen Herstellung
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
ATE393766T1 (de) Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen
DE60305400D1 (de) Anlage zur Behandlung von Produkten und dazugehörige Datenerfassungseinheit
ATE464901T1 (de) Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen
EP1715825A4 (de) Verfahren und vorrichtungen zur linderung von obstruktionen der oberen atemwege
ATE395062T1 (de) Kombination von opioiden und einem piperazin- derivat für die behandlung von schmerzen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1708790

Country of ref document: EP